Overview of Fexofenadin STADA

Property	Description
Active ingredient	Fexofenadine hydrochloride
Form	Oral tablets (or oral suspension)
Pharmacological class	Antihistamine (H1-receptor antagonist)
Common use	Relief of symptoms associated with allergic responses
Origin	Synthetic

The foundation of Fexofenadin STADA is its active ingredient, Fexofenadine, supplied as the salt form, Fexofenadine hydrochloride. This substance is a synthetic compound classified as a systemic anti-allergic medication intended for oral administration as a single-ingredient product. Its efficacy is clinically recognized for providing relief in conditions where the immune system overreacts to common triggers, such as pollen.

Classification and Action

Fexofenadine is categorized as a second-generation antihistamine. It functions specifically as a selective H1-receptor antagonist, which is its defined pharmacological class. The medicine acts by selectively blocking the action of histamine at its designated sites across the body, thus generally helping to mitigate the physical discomfort associated with various allergic responses.

Crucially, Fexofenadine is widely recognized as a non-sedating option, a key characteristic of the newer antihistamine generation. This unique property is a primary differentiating factor, as the drug’s design minimizes effects on the central nervous system, offering a profile that is generally preferred for managing daytime allergic discomfort without the marked drowsiness associated with some older antihistamines.

Pharmaceutical Preparation

The general purpose of this medication is to interrupt the allergic cascade. The oral preparation form, whether tablets or oral suspension, facilitates systemic absorption, allowing the active substance to circulate and affect H1-receptors across multiple body systems for comprehensive relief.

Regulatory References

NIH MedlinePlus Drug Information on Fexofenadine

What side effects are possible with Fexofenadin STADA?

Adverse Reactions and Safety Profile

Official regulatory documents classify adverse reactions to Fexofenadin STADA into frequency categories based on clinical trial data and additional reports from post-marketing surveillance.

Frequency-Classified Adverse Reactions

Classification	Common Reactions (Observed in trials at similar rates to placebo)
Common	Headache, drowsiness/fatigue, dizziness, nausea
Uncommon	Tiredness, sleepiness
Rare / Not Known	Insomnia, sleep disorders, nervousness, nightmares, blurred vision, diarrhea, skin rash, hives, pruritus, tachycardia, palpitations

Serious and Rare Adverse Events

Rare and very rare, but clinically significant, adverse reactions have been reported, primarily through post-marketing surveillance. These include hypersensitivity reactions such as angioedema (swelling of the face, lips, tongue, or throat), flushing, chest tightness, dyspnea (difficulty breathing), and systemic anaphylaxis (shock). Other serious events reported include liver dysfunction (sometimes presenting as jaundice or yellowing of the skin/eyes) and specific blood disorders (agranulocytosis, leucopenia, neutropenia).

Safety Considerations for Specific Populations and Interactions

Pregnancy and Breastfeeding: Data on use during pregnancy are limited, and the medicine is generally recommended only if the potential benefit justifies the potential risk. Excretion into human breast milk is not fully established.

Kidney and Liver Impairment: The drug’s elimination is altered in patients with decreased kidney function, which may lead to increased plasma levels. Caution and dose adjustments are advised in patients with kidney impairment and the elderly, who may have age-related reductions in kidney function. Caution is also advised for use in patients with pre-existing heart disease due to rare reports of cardiac rhythm disturbances.

Interactions Affecting Exposure: Concomitant use with antacids containing aluminum and magnesium hydroxide should be separated by about two hours, as these antacids can reduce the medicine's absorption. Additionally, the absorption and subsequent exposure to the drug may be significantly decreased when taken with certain fruit juices (e.g., grapefruit, apple, orange).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents strictly define the required response and clinical manifestations for a suspected overdose of Fexofenadine hydrochloride.

Documented Overdose Manifestations

Overexposure to the active substance may be characterized by several clinical signs documented in official labeling. The most frequently reported manifestations include central nervous system effects such as drowsiness (somnolence), dizziness, and generalized fatigue. Additionally, cases of overdosage have included reports of dry mouth. Cardiovascular involvement has also been observed, with regulatory sources documenting the occurrence of tachycardia (increased heart rate).

Emergency Actions and Management

Immediate medical attention must be sought in all cases of suspected overdose. Regulatory guidance explicitly states to seek immediate medical attention and contact a poison control center for advice. The management of Fexofenadine overdose is strictly defined as symptomatic and supportive treatment because no specific antidote is known. Management procedures may involve standard measures to remove any unabsorbed drug from the gastrointestinal tract, such as administration of activated charcoal or gastric lavage. Continuous hospital monitoring of the patient's clinical status may be required. Regulatory documents confirm that hemodialysis is not considered an effective method for removing the active substance from the blood.

Therapeutic Uses of Fexofenadin STADA

Fexofenadin STADA is relevant in contexts where supportive symptom management is needed for various allergic manifestations. It is commonly used across conditions characterized by periods of heightened symptoms like Seasonal Allergic Rhinitis (hay fever), and is applied in settings where patients experience dermal manifestations associated with Chronic Spontaneous Urticaria (CSU).

This medication helps address symptom clusters that may become intense or disruptive, such as frequent sneezing, excessive runny nose, symptoms related to inflammatory or irritative states such as itching of the eyes, throat, and nose, and the spontaneous appearance of wheals (hives/rash). It provides support that helps ease the overall symptom burden during periods of high allergen exposure or chronic flare-ups.

“This agent supports the patient by being non-sedating, which is a key benefit when symptoms interfere with routine activities.”

Quick Fact: Relief for Allergic Discomfort

Fexofenadin STADA is relevant for easing the impact of allergic symptoms on functional stability, supporting patients during difficult episodes while maintaining daytime alertness.

Regulatory References

NIH MedlinePlus overview of Fexofenadine

Eligibility and Restrictions for Use

Fexofenadin STADA is primarily intended for use by adults and children 12 years of age and older, though some specific formulations and indications are approved for children as young as six months to two years, depending on the regulatory region and product label.

Populations Who Must Not Use the Medicine (Contraindications)

Use is strictly contraindicated in patients with a known hypersensitivity (allergic reaction) to fexofenadine hydrochloride or any of the inactive ingredients present in the specific formulation.

Populations Requiring Special Consideration

Use of Fexofenadin STADA is conditional or requires special care in several groups:

Patients with Impaired Kidney Function: Clearance of the medicine is reduced in those with decreased renal function. A lower starting dose is officially recommended for both adults and pediatric patients with impaired kidney function.
The Elderly: Use in patients 65 years and older should be approached with caution due to the higher likelihood of age-related decline in kidney function.
Pregnancy: The medicine is not generally recommended for use during pregnancy; it should only be used if the potential benefit is determined to clearly justify the potential risk to the fetus.
Breastfeeding: Use is not recommended while breastfeeding, as the active substance may be excreted into human milk.
Children: Specific age cut-offs apply; for example, the safety and effectiveness of all forms have not been established in infants under six months of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fexofenadine STADA's official interaction profile is characterized by pharmacokinetic changes resulting from interference with drug transporters.

Documented Pharmacokinetic Interactions

Fexofenadine is a substrate for the drug efflux transporter P-glycoprotein (P-gp) and the uptake transporter Organic-Anion-Transporting Polypeptide (OATP). Co-administration with certain inhibitors of these transporters leads to significantly altered exposure.

Interacting Product Category	Effect on Fexofenadine Exposure	Clinical Consequence
P-gp Inhibitors (e.g., Erythromycin, Ketoconazole)	Plasma levels increase (up to 2-3 times)	Increased systemic exposure
P-gp Inducers (e.g., Apalutamide)	Plasma levels decrease (e.g., 30% reduction in AUC)	Decreased systemic exposure
Antacids (Aluminum/Magnesium Hydroxide Gels)	Bioavailability is significantly reduced	Reduced drug absorption

Timing and Product-Specific Constraints

The interaction with Aluminum and Magnesium Hydroxide antacids necessitates a separation of at least two hours between the administration of Fexofenadine STADA and the antacid. This is to minimize binding in the gastrointestinal tract and prevent reduced drug absorption.

Furthermore, consumption of fruit juices (such as grapefruit, orange, or apple juice) is documented to decrease fexofenadine's systemic exposure and peak plasma concentration, and is therefore discouraged during treatment. Fexofenadine undergoes negligible hepatic metabolism, meaning interactions through Cytochrome P450 enzymes are not expected.

Mechanism of Action

Molecular Mechanism: Selective H1 Receptor Blockade

Fexofenadine operates by stabilizing the peripheral Histamine H1 Receptor in its inactive conformation, functioning as a selective inverse agonist. This action directly and efficiently prevents the binding of endogenous histamine, thereby suppressing the initiation of the H1 receptor signaling cascade at the molecular level. This blockade leads to the physiological consequence of reduced signal transduction responsible for histamine-mediated activity.

Localized Action: Restriction from the Central Nervous System

The drug's mechanism is engineered for a predominantly peripheral effect through its chemical properties and active transport. Fexofenadine is a substrate for the P-glycoprotein efflux transporter, which actively pumps the molecule away from the brain at the blood-brain barrier. This intentional restriction ensures that H1 receptor blockade is minimized in the CNS, leading to the physiological consequence of minimal central H1 signaling and the maintenance of central neurological pathways.

Pathway Modulation: Limiting Systemic Leakage and Signaling

By interrupting the H1 R cascade, Fexofenadine modifies critical physiological processes, including the regulation of microvascular permeability and the stimulation of sensory nerve endings. This mechanistic adjustment helps reduce the localized leakage of fluid from blood vessels and dampens the neural signal responsible for itching. The mechanism also includes a secondary effect on the modulation of other inflammatory mediators, which contributes to the overall reduction of tissue fluid accumulation and localized inflammatory processes.

Dosage and Administration Information

How to Use Fexofenadin STADA — Administration Guidelines

This section outlines the instructions for the use of Fexofenadin STADA (Fexofenadine Hydrochloride) film-coated tablets, based on prescribing information.

Administration Scope

Instruction	Detail
Route of Administration	Oral (by mouth). The tablet must be swallowed whole.
Dosing Schedule	The standard doses for adults and children 12 years and over are either 120 mg or 180 mg film-coated tablets.
Frequency	Once daily (q.d.). Do not exceed one tablet in 24 hours.
Timing in Relation to Meals	The tablet must be taken before a meal.

Special Procedural Conditions

Adherence to the following conditions is important for proper use and absorption:

Liquid Intake: The tablet should be taken with water. It must not be consumed with fruit juices (e.g., grapefruit, apple, or orange juice), as these can reduce the medicine's absorption.
Antacids: A period of approximately 2 hours must be allowed between taking Fexofenadin STADA and taking antacids that contain aluminum or magnesium hydroxide.
Missed Dose: If a dose is forgotten, the next dose should be taken at the usual time. Do not take a double dose to compensate for the missed tablet.

Age-Group and Special Patient Rules

Children: The 120 mg and 180 mg tablet strengths are indicated for use in adults and children 12 years of age and older.
Kidney Impairment: Patients with impaired kidney function may require dose adjustment. They should seek guidance to determine the appropriate regimen.

Recent Clinical Evidence

Fexofenadin STADA: Recent Clinical Evidence

Clinical research into fexofenadine, the active substance in Fexofenadin STADA, has focused primarily on its use for seasonal allergic rhinitis (SAR) and chronic idiopathic urticaria (CIU), commonly known as chronic hives.

Efficacy and Symptom Relief

Allergic Rhinitis: Pooled data from randomized, placebo-controlled trials, including large meta-analyses, show a consistent association between fexofenadine use and a change in total symptom scores (TSS) in adults and adolescents with allergic rhinitis compared to placebo. Individual nasal and non-nasal symptoms such as sneezing, runny nose, and itchy, watery eyes were also investigated and reported to have changed over the study periods. For children aged 6 to 11 years, studies have evaluated lower doses for their potential effects on SAR symptoms.

Chronic Urticaria: In studies evaluating chronic idiopathic urticaria, fexofenadine was compared to placebo and investigated for its effect on symptoms. Research reported a change in the severity of pruritus (itching) and the number of wheals (hives) over 4-week treatment periods. These trials also examined how the compound's use was associated with reported interference with sleep and daily activities due to CIU.

Safety and Tolerability Profile

Fexofenadine is classified as a second-generation antihistamine. Clinical trials have widely evaluated its safety profile, noting that the frequency of reported adverse events (AEs), such as headache or nausea, was generally similar to that of the placebo group. A significant finding across multiple studies is the minimal penetration of the blood-brain barrier, which contributes to its generally low reported incidence of sedation or cognitive side effects compared to first-generation antihistamines. The compound is mainly excreted unchanged, primarily through the feces, with minimal metabolism in the liver. Dose adjustment is typically considered for individuals with decreased renal function due to altered elimination kinetics observed in this population.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Fexofenadin STADA (FAQ)

Q: Is Fexofenadin STADA used only for hay fever?

No, according to official product information, Fexofenadin STADA is indicated for the symptomatic relief of two main conditions. These include Seasonal Allergic Rhinitis (commonly known as hay fever) and Chronic Idiopathic Urticaria (commonly known as chronic hives).

Q: Is Fexofenadin STADA an effective treatment for skin rashes or eczema?

It is indicated for Chronic Idiopathic Urticaria, which involves hives (wheals) and itching. Regulatory documents do not specifically list other forms of skin rash or eczema as indications for this treatment.

Q: What are the general benefits of taking Fexofenadin STADA?

The main benefit of Fexofenadin STADA is the symptomatic relief it provides for allergic conditions. This includes reducing the specific signs and discomfort associated with seasonal allergic rhinitis and chronic idiopathic urticaria.

Q: How quickly does Fexofenadin STADA typically start to work after taking a dose?

Official information indicates that the antihistaminic effect generally begins within one hour after taking the tablet. The full maximum effect may take slightly longer to be reached.

Q: Is Fexofenadin STADA meant for long-term or short-term use?

The drug controls symptoms of allergic rhinitis and urticaria but does not cure them. Official information describes that the product is intended to control symptoms as they occur, but does not provide a cure.

Q: Are there any known long-term side effects linked to taking Fexofenadin STADA?

Adverse events reported are based on clinical trials and post-marketing surveillance over defined periods. There is limited data in long-term continuous use. For this reason, official guidance documents suggest that the product is used only for the necessary duration.

Q: Is Fexofenadin STADA known to cause weight changes?

Weight increase has been reported in post-authorization safety data, but it is not listed as a common side effect in clinical trial data.

Q: What is the official information regarding Fexofenadin STADA and alcohol consumption?

Official patient information states that concurrent consumption of alcohol with fexofenadine should be approached cautiously, as it may be associated with increased sleepiness.

Q: Can Fexofenadin STADA cause stomach upset?

Yes, official adverse event reports have noted occasional gastrointestinal side effects. These can include common issues such as nausea, vomiting, indigestion, or diarrhea.

Q: Is it safe to take Fexofenadin STADA alongside a steroid nasal spray?

Official sources, such as public health information, indicate that fexofenadine has no known interactions with many hay fever treatments, including steroid nasal sprays, that would prevent their concurrent use.

Q: Does Fexofenadin STADA affect the use of hormonal contraceptives?

Official information indicates that Fexofenadine does not affect the effectiveness of any type of hormonal birth control. This includes the combined oral contraceptive pill or emergency contraception.

Q: Is Fexofenadin STADA considered appropriate for use by elderly patients?

Caution is advised for use in patients aged 65 and older, as indicated in regulatory documents. This is due to the higher likelihood of age-related kidney problems, which may require a dose adjustment for the elderly patient.

Q: How does Fexofenadin STADA differ from first-generation antihistamines?

Fexofenadine is classified as a second-generation antihistamine and is known for being highly selective for the H1-receptor. A key difference from first-generation drugs is its minimal to no sedative or anticholinergic effects, as it does not readily cross the blood-brain barrier.

Q: Can Fexofenadin STADA be purchased without a prescription in some countries?

The regulatory status of fexofenadine varies depending on the region or country. In some regulatory regions, it has been made available over-the-counter (OTC) for consumers, while in others, it may require a prescription.

Q: Is the active ingredient of Fexofenadin STADA available in a liquid or suspension form for children?

Yes, the active ingredient, Fexofenadine, is available in an oral suspension (liquid) form in some authorized regions. This liquid form is sometimes indicated for use in children as young as 6 months.

Q: What is the general difference in effect between the 120 mg and 180 mg strengths of Fexofenadin STADA?

Official product information shows that the different strengths are approved for different authorized conditions. For example, the 120 mg strength is typically indicated for Seasonal Allergic Rhinitis, while the 180 mg strength is typically approved for Chronic Idiopathic Urticaria.

Q: Is it normal to not notice the full effect of the medicine immediately after the first dose?

Yes, while the antihistaminic effect begins quickly, official efficacy data indicates that the full maximum antihistaminic effect may be reached up to 6 hours after taking a dose. This time frame can vary among individuals.

Q: How does Fexofenadin STADA affect the ability to drive a vehicle or operate machinery?

Official documents describe that the product is generally associated with minimal CNS effects, and it is typically not expected to impair the ability to drive or operate machinery. However, individual responses to any medication can vary, and this should be taken into account.

Q: What is the recommendation if symptoms do not seem to improve after starting Fexofenadin STADA?

If a person’s symptoms do not show improvement or if they appear to worsen, official patient information indicates that a person is advised to consult a healthcare professional or pharmacist.

Q: What research studies have been conducted on the long-term effectiveness of fexofenadine?

Official clinical reviews confirm that the long-term safety of fexofenadine has been assessed over periods lasting up to 12 months in some studies. However, the compound's effectiveness in managing symptoms is mainly documented through short-term, placebo-controlled trials.

Q: What is the scientific half-life of fexofenadine in the human body?

According to official clinical pharmacology data, the terminal elimination half-life of fexofenadine is the time it takes for half of the drug to be eliminated from the body. This period typically ranges from 11 to 15 hours after multiple dosing.

Q: Does Fexofenadin STADA interact with herbal supplements like St. John's Wort?

There is not enough official information in regulatory documents to definitively confirm the safety profile of fexofenadine when combined with all herbal remedies. Official documentation does not provide definitive safety information for all possible herbal remedies.

Q: Is Fexofenadin STADA known to interact with common pain relievers?

Public health information reports no known interactions between fexofenadine and common over-the-counter pain relievers such as Paracetamol or Ibuprofen.

Q: Can Fexofenadin STADA be used to manage perennial allergies (symptoms all year round)?

Fexofenadine is primarily indicated for Seasonal Allergic Rhinitis (SAR) and Chronic Idiopathic Urticaria (CIU). Perennial use, meaning symptoms experienced consistently all year round, is not explicitly listed as a primary indication in all regulatory documents.

Q: Does the effectiveness of Fexofenadin STADA typically remain consistent with continued use over a season?

Clinical trials for allergic rhinitis and urticaria showed consistent efficacy in providing symptom relief over the 4-week trial periods examined. These findings support its efficacy throughout the time period studied in the trials.

How should Fexofenadin STADA be stored and disposed of?

How to Store and Dispose of Fexofenadin STADA (Fexofenadine Hydrochloride)

Storage Conditions

Fexofenadine hydrochloride tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and excessive moisture, and should be kept from freezing or extreme heat. To maintain stability, the tablets must remain in the original container or package until use.

Child Safety and Disposal

This medication is required to be stored out of the sight and reach of children at all times. Do not use the medicine past its documented expiry date. Any unused or expired Fexofenadine STADA must be discarded in accordance with local regulations for pharmaceutical waste, and should not be thrown into household trash or wastewater.

Fexofenadin STADA